HS
MAZE

HighVista Strategies’s Maze Therapeutics MAZE Stock Holding History

HighVista Strategies’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08M Buy
136,572
+36,722
+37% +$962K 0.93% 34
2026
Q1 		$2.98M Sell
99,850
-70,503
-41% -$3.11M 0.82% 38
2025
Q4 		$7.06M Buy
+170,353
New +$5.85M 1.82% 11

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

HighVista Strategies's MAZE Position: Q2 2026 in Review

HighVista Strategies increased its Maze Therapeutics (MAZE) stake by 37% in Q2 2026, buying an estimated $962K and bringing the position to 136,572 shares worth $4.08M. The position accounts for 0.93% of the portfolio, ranked #34.

HighVista Strategies first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.06M in Q4 2025. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • HighVista Strategies held 136,572 shares of Maze Therapeutics worth $4.08M as of Q2 2026.
  • HighVista Strategies bought 36,722 Maze Therapeutics shares in Q2 2026, an estimated $962K.
  • Maze Therapeutics made up 0.93% of HighVista Strategies's portfolio in Q2 2026, its #34 holding.
  • HighVista Strategies first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • HighVista Strategies's Maze Therapeutics position peaked at $7.06M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.